FDA Updates Clinical Benefit List for Non-Malignant and Neurological Accelerated Approvals
FDA's updated verified clinical benefit list covers 14 non-malignant and neurological AA conversions, offering regulatory teams concrete timeline benchmarks.


Conversion timelines from accelerated to traditional approval are now measurable across 14 listed indications, following the FDA's November 2026 update to its verified clinical benefit registry for non-malignant hematological, neurological, and other disorder indications. For regulatory affairs leads managing postmarket commitments, the updated listing provides a concrete benchmark against which confirmatory trial timelines can be assessed.
The registry spans approvals dating from 1997 to 2026, with conversion intervals ranging from under seven months to nearly a decade. At the shorter end, Leqembi (lecanemab-irmb) moved from accelerated approval in January 2023 to traditional approval in July 2023, a six-month conversion. Fabhalta (iptacopan), granted accelerated approval in August 2024 for primary IgAN, achieved traditional approval by July 2026, a roughly 23-month interval. Provayblue (methylene blue), by contrast, carried accelerated approval status from April 2016 until January 2024, nearly eight years before conversion.
The variance in conversion timelines reflects the complexity of confirmatory trial design across therapeutic areas rather than any uniform agency expectation. Regulatory affairs teams benchmarking their own postmarket study commitments against this data should account for indication-specific endpoint complexity, patient population size, and trial infrastructure when projecting conversion windows. The FDA's Postmarket Requirements and Commitments database remains the authoritative source for status of specific study obligations.
The listing also carries an administrative note relevant to compliance records: total approval time for certain legacy entries was adjusted based on management decision, a practice the agency states is no longer exercised. QA directors and regulatory leads maintaining submission histories should verify that internal documentation reflects the dates published in Drugs@FDA rather than any previously adjusted figures.
Three IgAN indications now appear on the verified list, covering Tarpeyo (budesonide), Filspari (sparsentan), and Fabhalta (iptacopan), signaling that the agency has accepted proteinuria reduction as a surrogate endpoint capable of supporting full approval in this indication when confirmatory data are robust. Sponsors in adjacent nephrology programs will find the conversion precedents directly applicable to endpoint strategy discussions.
The registry will continue to update as product labeling revisions or Federal Register notices confirm status changes, making periodic review a routine checkpoint for regulatory affairs teams tracking the accelerated approval landscape.
Source: FDA Drugs Accelerated Approval Program via What's New: Drugs RSS Feed, 19 November 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.



Discussion